Phase 4 clinical trial assessing AD-101
Latest Information Update: 08 Jun 2022
At a glance
- Drugs AD 101 AmyriAD (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
Most Recent Events
- 08 Jun 2022 New trial record
- 01 Jun 2022 According to AmyriAD media release, under terms of the new contract, which is valued at nearly $1.0 million, Societal will execute a range of clinical trial services to support the initiation of Phase 3 and this Phase 4 clinical studies of AD101.